Allison Barz Leahy, MD MSCE
Assistant Professor of Pediatrics (Oncology) at the Children's Hospital of Philadelphia
Core Faculty, Clinical Futures, Children's Hospital of Philadelphia
Innovation Faculty Member, Penn Center for Cancer Care Innovation, University of Pennsylvania
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
HUB For Clinical Collaboration
3500 Civic Center Boulevard
Philadelphia, PA 19104
HUB For Clinical Collaboration
3500 Civic Center Boulevard
Philadelphia, PA 19104
Office: 267-253-8133
Email:
barza@chop.edu
barza@chop.edu
Education:
BA (Russian Language Major, Chemistry Minor)
Bowdoin College , 2005.
MA (Biological Sciences)
Hunter College of the City of New York, 2008.
MD
SUNY Upstate Medical University, 2012.
MSCE
University of Pennsylvania, 2020.
Permanent linkBA (Russian Language Major, Chemistry Minor)
Bowdoin College , 2005.
MA (Biological Sciences)
Hunter College of the City of New York, 2008.
MD
SUNY Upstate Medical University, 2012.
MSCE
University of Pennsylvania, 2020.
Description of Clinical Expertise
Patient-reported outcomes (PROs), relapsed and refractory leukemia, CAR T cellsDescription of Research Expertise
Patient-reported outcomes (PROs), pediatric health outcomes, phase 1 clinical trials, relapsed and refractory leukemia, pediatric oncologySelected Publications
Newman H, Li Y, Huang YSV, Elgarten CW, Myers RM, Ruiz J, Zheng DJ, Barz Leahy A, Aftandilian C, Arnold SD, Bona K, Gramatges MM, Heneghan MB, Maloney KW, Modi AJ, Mody RJ, Morgan E, Rubnitz J, Winick N, Wilkes JJ, Seif AE, Fisher BT, Aplenc R, Getz KD: Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research. Cancer Med. Apr 2024.Winestone LE, Bhojwani D, Ghorashian S, Muffly L, Barz-Leahy A, Chao K, Steineck A, Rossig C, Lamble A, Maude SL, Myers R, Rheingold SR: INSPIRED Symposium Part 4A: Access to CAR T cell Therapy in Unique Populations with B-cell Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy. Elsevier, Oct 2023.
Machietto R, Giacobbe N, Perazzelli J, Hofmann TJ, Barz Leahy A, Grupp SA, Wang Y, Kadauke S.: Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor. J Vis Exp (198, Aug 2023.
Machietto M, Giacobbe N, Perazzelli J, Hofmann TJ, Leahy AB, Grupp SA, Wang YP, Kadauke S, : Chimeric Antigen Receptor (CAR) T Cell Manufacturing on an Automated Cell Processor. Journal of Visualized Experiments Aug 2023.
Friedes B, DiNofia AM, Li Y, Iannone E, Rheingold SR, Leahy AB, Wray L, Callahan C, Baniewicz D, Liu H, Getz K, Aplenc R, Maude SL, Grupp SA, Myers RM : Salvage therapies and outcomes of patients with relapse of B-ALL after CD19 CAR T-cell therapy. ASPHO Conference, Fort Worth, TX May 2023.
Newman H, Li Y, Liu H, Myers RM, Tam V, DiNofia A, Wray L, Rheingold SR, Callahan C, White C, Baniewicz D, Winestone LE, Kadauke S, Diorio C, June CH, Getz K, Aplenc R, Teachey DT, Maude SL, Grupp SA, Bona K, Barz Leahy A.: Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Blood 141: 609-619, Feb 2023.
Newman H, Li Y, Huang YSV, Elgarten C, Myers RM, Ruiz J, Leahy AB, Aftandilian C, Arnold S, Bona K, Heneghan M, Gramatges MM, Maloney K, Modi AJ, Mody R, Morgan E, Winick N, Wilkes J, Seif A, Fisher BT, Aplenc R, Getz KD: Influence of household income on health-related quality of life and toxicity in children with acute myeloid leukemia. Abstract, 64th ASH Annual Meeting and Exposition, New Orleans, LA Dec 2022.
Myers RM, DiNofia AM, Li Y, Diorio C, Aplenc R, Baniewicz D, Brogdon JL, Callahan C, Engels B, Fraietta JA, Gonzalez V, Iannone E, Leahy AB, Liu H, McClory SE, Rheingold SR, Shinehouse L, Wertheim G, Wray L, Frey NV, Maude SL, Grupp SA : CD22-Targeted CAR-Modified T-CellsSafely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment withCD19-Targeted CAR T-Cells. Oral Presentation, 64th ASH Annual Meeting and Exposition, New Orleans, LA Dec 2022.
Reeve BB, Hernandez A, Freyer DR, Linder LA, Embry L, Leahy AB, Baker JN, Mack JW, McFatrich M, Henke DM, Mowbray C, Jacobs SS, Maurer SH, Gold SH, Hinds PS.: Capturing the young child's reports of cancer treatment tolerability: Does our practice reflect an assumption that they cannot report? Pediatr Blood Cancer Oct 2022.
Ceolin V, Brivio E, van Tinteren H, Rheingold SR, Leahy A, Vormoor B, O'Brien MM, Rubinstein JD, Kalwak K, De Moerloose B, Jacoby E, Bader P, López-Duarte M, Goemans BF, Locatelli F, Hoogerbrugge P, Calkoen FG, Zwaan CM.: Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia. Leukemia Oct 2022.